Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVERGRANDE HEALTH INDUSTRY GROUP LIMITED

恒大健康產業集團有限公司

(a company incorporated in Hong Kong with limited liability)

(Stock code: 708)

CHANGE OF EXECUTIVE DIRECTOR

The board of directors (the "Board" and each "Director") of Evergrande Health Industry Group Limited (the "Company") hereby announces that Mr. Li Siquan has resigned from his position as an executive Director of the Company, and Mr. Qin Liyong has been appointed as an executive Director, with effect from 1 February 2019. Biographical details of the newly appointed director Mr. Qin Liyong are set out below.

APPOINTMENT OF EXECUTIVE DIRECTOR

Mr. Qin Liyong ("Mr. Qin"), aged 41, works in the field of engineering management and supervision for more than 16 years. Mr. Qin graduated from Tongji University, majoring in engineering management, and subsequently graduated from Tongji University with a master's degree in management science and engineering. Prior to joining the Company, Mr. Qin was the assistant general manager and project engineer of Shanghai Jia'an Real Estate Co. Ltd* (上海佳安置業有限公司). He subsequently joined Hengda Real Estate Group, where he served as the manager and vice manager of the integrated planning department of management supervision center from 2005 to 2007. He held senior management positions such as the general manager and deputy general manager at the management center from 2007 to 2012. He was the vice president and general manager at the leadership, management and supervision center of the Company from 2012 to 2015. He served various positions including the chairman and general manager of Hengda Real Estate Group Grain and Oil Group* (恒大地產集團糧油集團), Hengda Real Estate Group Shenzhen Company* (恒大地產集團深圳公司) and Hengda Real Estate Group Heilongiang Company* (恒大地產集團黑龍江公司) from 2015 to 2018. Before his appointment as an executive Director of the Company, Mr. Qin was the vice president and executive vice president of the Group.

Mr. Qin has entered into a service contract with the Company for a term of three years, and is subject to retirement by rotation at least once every three years and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (the

"Listing Rules"). The monthly Director's remuneration of Mr. Qin will be RMB15,000 (excluding any additional service compensation and discretionary bonus), which is determined with reference to his duties and responsibilities as a Director, his qualification and experience, as well as the prevailing market conditions.

As of the date of this announcement, Mr. Qin held 6 million shares in Hengten Networks Group Limited (whose shares are listed on the Main Board of the Stock Exchange, stock code: 136), an associated corporation of the Company; and 2.14 million shares and 2 million share options in China Evergrande Group (whose shares are listed on the Main Board of the Stock Exchange, stock code: 3333), an associated corporation of the Company.

Save as disclosed above, to the knowledge of the Company, Mr. Qin, as of the date of this announcement,

- (1) has not held any other directorships in any other listed public companies in the last three years and does not have any relationship with any Director, senior management or substantial or controlling shareholder of the Company;
- (2) does not have any interests in the shares of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong);
- (3) does not hold any other position in the Company or any of its subsidiaries; and
- (4) has no other information that is required to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, nor is there any matter that needs to be brought to the attention of the holders of the securities of the Company in relation to his appointment as a Director.

The Company would like to express its warm welcome to Mr. Qin in joining the Board.

RESIGNATION OF EXECUTIVE DIRECTOR

Mr. Li Siquan ("Mr. Li") has resigned as an executive Director with effect from 1 February 2019 due to his redesignation to a subsidiary of China Evergrande Group. Mr. Li confirmed that he had no disagreement with the Board and there was no matter relating to his resignation that needs to be brought to the attention of the holders of the securities of the Company. The Board would like to express its sincere gratitude to Mr. Li for his valuable contribution to the Company during his term of office.

By Order of the Board

Evergrande Health Industry Group Limited

Shi Shouming

Chairman

Hong Kong, 1 February 2019

As at the date of this announcement, the executive Directors of the Company are Mr. SHI Shouming, Mr. PENG Jianjun and Mr. QIN Liyong; and the independent non-executive Directors of the Company are Mr. CHAU Shing Yim David, Mr. GUO Jianwen and Mr. XIE Wu.

* For identification purpose only